Form 8-K - Current report:
SEC Accession No. 0001193125-26-008907
Filing Date
2026-01-09
Accepted
2026-01-09 16:05:23
Documents
14
Period of Report
2026-01-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d69982d8k.htm   iXBRL 8-K 26131
2 EX-99.1 d69982dex991.htm EX-99.1 27171
6 GRAPHIC g69982g0109030931336.jpg GRAPHIC 6503
  Complete submission text file 0001193125-26-008907.txt   187512

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tern-20260107.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tern-20260107_lab.xml EX-101.LAB 18735
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tern-20260107_pre.xml EX-101.PRE 11713
16 EXTRACTED XBRL INSTANCE DOCUMENT d69982d8k_htm.xml XML 3782
Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Filer) CIK: 0001831363 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39926 | Film No.: 26523089
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)